Fate Therapeutics (FATE) Short term Debt (2012 - 2019)

Fate Therapeutics' Short term Debt history runs 8 years deep, the most recent figure standing at $13.9 million for Q3 2019.

• Quarterly Short term Debt rose 326.84% year-over-year to $13.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $13.9 million (up 326.84% YoY) and the FY2018 annual result came in at $2.4 million, changed N/A from the prior year.
• Short term Debt was $13.9 million for Q3 2019 at Fate Therapeutics, up from $5.4 million in the prior quarter.
• Across five years, Short term Debt topped out at $13.9 million in Q3 2019 and bottomed at $758000.0 in Q1 2018.
• A 5-year average of $5.9 million and a median of $6.0 million in 2015 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2015 — Short term Debt surged 962.85% — and 2018, when it slumped 90.12%.
• Fate Therapeutics' Short term Debt stood at $7.7 million in 2015, then increased by 6.48% to $8.2 million in 2016, then slipped by 6.3% to $7.7 million in 2017, then plunged by 68.22% to $2.4 million in 2018, then soared by 471.45% to $13.9 million in 2019.
• Business Quant data shows FATE's Short term Debt at $13.9 million in Q3 2019, $5.4 million in Q2 2019, and $3.9 million in Q1 2019.